Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.005
Sell
RSI(14)
42.411
Neutral
STOCH(KDJ)(9,3,3)
19.491
Sell
ATR(14)
0.055
Low Volatility
CCI(14)
-89.875
Neutral
Williams %R
85.714
Oversold
TRIX(12,20)
-0.529
Sell
StochRSI(14)
39.530
Sell
Canopy Growth Corp
CGC1.100USD
+0.020+1.85%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
365.62MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Canopy Growth Corp
Currency: USD Updated: 2026-02-06Key Insights
Canopy Growth Corp's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 102 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 2.50.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Canopy Growth Corp's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
Canopy Growth Corp Highlights
StrengthsRisks
Canopy Growth Corporation is a Canada-based cannabis company. The principal activities of the Company are the production, distribution and sale of a diverse range of cannabis and cannabinoid-based products for both adult-use and medical purposes under a portfolio of distinct brands in Canada. The Company delivers innovative products from owned and licensed brands, including Tweed, 7ACRES, DOJA, Deep Space, and Claybourne, as well as category defining vaporization devices by Storz & Bickel. Its segments include Canada cannabis, and Storz & Bickel. Its Canada cannabis segment includes the production, distribution, and sale of a range of cannabis, hemp, and cannabis related products in Canada. Its Storz & Bickel segment includes the production, distribution, and sale of vaporizers. In addition, it serves medical cannabis patients globally with principal operations in Canada, Europe and Australia.
Undervalued
The company’s latest PE is -0.81, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 38.22M shares, decreasing 0.04% quarter-over-quarter.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.73.
Analyst Rating
Based on
2
analysts
Hold
Current Rating
2.500
Target Price
+131.48%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-02-06The current financial score of Canopy Growth Corp is 8.59, ranking 55 out of 159 in the Pharmaceuticals industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 54.31M, representing a year-over-year increase of 3.85%, while its net profit experienced a year-over-year increase of 46.49%.
Score
Financials
7.78
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
10.00
Operational Efficiency
10.00
Growth Potential
7.88
Shareholder Returns
7.29
Canopy Growth Corp's Company Valuation
Currency: USD Updated: 2026-02-06The current valuation score of Canopy Growth Corp is 8.74, ranking 8 out of 159 in the Pharmaceuticals industry. Its current P/E ratio is -0.81, which is -91.67% below the recent high of -0.07 and -253.62% above the recent low of -2.87.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 102/159
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-02-06The current earnings forecast score of Canopy Growth Corp is 6.00, ranking 135 out of 159 in the Pharmaceuticals industry. The average price target is 3.65, with a high of 3.65 and a low of 3.65.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
2
analysts
Hold
Current Rating
2.500
Target Price
+131.48%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
173
Total
6
Median
8
Average
Company name
Ratings
Analysts
Canopy Growth Corp
CGC
2
Biogen Inc
BIIB
36
Amgen Inc
AMGN
35
Eli Lilly and Co
LLY
33
Vertex Pharmaceuticals Inc
VRTX
33
Gilead Sciences Inc
GILD
31
1
2
3
...
35
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-02-06The current price momentum score of Canopy Growth Corp is 4.36, ranking 149 out of 159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 1.26 and the support level at 1.01, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
1.120
Sell
MA10
1.130
Sell
MA20
1.164
Sell
MA50
1.244
Sell
MA100
1.270
Sell
MA200
1.311
Sell
Institutional Confidence
Currency: USD Updated: 2026-02-06Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Risk Assessment
Currency: USD Updated: 2026-02-06The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Canopy Growth Corp is 2.98, ranking 111 out of 159 in the Pharmaceuticals industry. The company's beta value is 2.40. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
2.40
VaR
+9.51%
240-Day Maximum Drawdown
+48.88%
240-Day Volatility
+109.71%
Return
Best Daily Return
60 days
+53.98%
120 days
+53.98%
5 years
+81.37%
Worst Daily Return
60 days
-12.43%
120 days
-17.22%
5 years
-40.91%
Sharpe Ratio
60 days
+0.53
120 days
-0.15
5 years
-0.35
Risk Assessment
Maximum Drawdown
240 days
+48.88%
3 years
+95.64%
5 years
+99.71%
Return-to-Drawdown Ratio
240 days
-0.66
3 years
-0.33
5 years
-0.20
Skewness
240 days
+2.04
3 years
+3.17
5 years
+2.98
Volatility
Realised Volatility
240 days
+109.71%
5 years
+106.65%
Standardised True Range
240 days
+11.14%
5 years
+230.25%
Downside Risk-Adjusted Return
120 days
-31.17%
240 days
-31.17%
Maximum Daily Upside Volatility
60 days
+137.70%
Maximum Daily Downside Volatility
60 days
+72.83%
Liquidity
Average Turnover Rate
60 days
+12.55%
120 days
+9.15%
5 years
--
Turnover Deviation
20 days
+72.99%
60 days
-3.41%
120 days
-29.59%
Peer Comparison
Pharmaceuticals
Canopy Growth Corp
CGC
6.13 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Mckesson Corp
MCK
9.07 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Gilead Sciences Inc
GILD
8.92 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
United Therapeutics Corp
UTHR
8.86 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Regeneron Pharmaceuticals Inc
REGN
8.72 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Mirum Pharmaceuticals Inc
MIRM
8.70 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
